Current CDC Travel Health Notices show no Level 4 designations as of late May 2026, with ongoing Ebola outbreaks in Central and East Africa addressed through targeted entry screening and restrictions rather than broad “Avoid All Travel” advisories. Dengue activity prompted only Level 1 notices for 16 countries earlier this year, consistent with historical patterns where Level 4 requires extreme, precaution-resistant health risks rarely met by current surveillance data. Trader consensus at 76.5% “No” reflects the low likelihood of a qualifying escalation before year-end absent major shifts in case trajectories or new pathogens. Upcoming CDC and WHO updates on regional transmission rates will be key monitoring points.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoIl CDC emette un avviso di livello 4 entro il 31 dicembre?
Sì
$71,809 Vol.
$71,809 Vol.
Sì
$71,809 Vol.
$71,809 Vol.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Mercato aperto: Jan 19, 2026, 3:15 PM ET
Resolver
0x65070BE91...A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Current CDC Travel Health Notices show no Level 4 designations as of late May 2026, with ongoing Ebola outbreaks in Central and East Africa addressed through targeted entry screening and restrictions rather than broad “Avoid All Travel” advisories. Dengue activity prompted only Level 1 notices for 16 countries earlier this year, consistent with historical patterns where Level 4 requires extreme, precaution-resistant health risks rarely met by current surveillance data. Trader consensus at 76.5% “No” reflects the low likelihood of a qualifying escalation before year-end absent major shifts in case trajectories or new pathogens. Upcoming CDC and WHO updates on regional transmission rates will be key monitoring points.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti